HUTCHMED (LON:HCM) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Shares of HUTCHMED (China) Limited (LON:HCM – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 198.87 and traded as low as GBX 169.50. HUTCHMED shares last traded at GBX 173.50, with a volume of 12,410 shares trading hands.

HUTCHMED Price Performance

The company has a current ratio of 4.96, a quick ratio of 2.97 and a debt-to-equity ratio of 7.91. The stock has a market cap of £1.50 billion, a PE ratio of 3.29 and a beta of 0.43. The company’s 50 day moving average is GBX 170.49 and its 200-day moving average is GBX 198.64.

Get HUTCHMED alerts:

HUTCHMED Company Profile

(Get Free Report)

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).

See Also

• Five stocks we like better than HUTCHMED
• Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
• Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
• Moog Is More Than a Missile Maker, and Wall Street Is Noticing
• A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.